Technology
Health
Pharmaceutical
Xeris Pharmaceuticals
$10.109876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$10.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.40 (-3.81%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell XERS and other stocks, options, ETFs, and crypto commission-free!
About
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSolâ„¢ and XeriJectâ„¢ formulation technologies. Read More The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Employees
90
Headquarters
Chicago, Illinois
Founded
2005
Market Cap
218.49M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
143.82K
High Today
$10.54
Low Today
$10.06
Open Price
$10.51
Volume
106.65K
52 Week High
$27.98
52 Week Low
$8.67
Collections
Technology
Health
Pharmaceutical
2018 IPO
US
North America
News
Associated PressMar 14
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
CHICAGO--(BUSINESS WIRE)--Mar 14, 2019--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia (EIH). “Many individuals with diabetes...
Simply Wall StFeb 26
What You Must Know About Xeris Pharmaceuticals, Inc.’s (NASDAQ:XERS) Financial Strength
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While small-cap stocks, such as Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) with its market cap of US$264m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. Companies operating in the Pharmaceuticals industry, especially ones that are currently loss-making, are more likely to be higher risk. So, under...
Markets InsiderFeb 20
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference. Date: Wednesday, February 27, 2019 Time: 3:30 p.m. ET Place: L...
Price Paid on Robinhood
13% Lower
Right Now
52 Week Low
$8.67
Average Price Paid
$11.66
52 Week High
$27.98
Earnings
-$0.98
-$0.89
-$0.80
-$0.71
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.94 per share
Actual
-$0.98 per share